Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 10, 2006, Pages 539-543

  Wiesli, Peter ^a,b   Lehmann, R ^a   Krayenbuehl, P A ^a   Schmid, C ^a   Spinas, G A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kantonsspital Frauenfeld   (Switzerland)

Author keywords

C peptide; Fast; Insulin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 33846180640     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-956512     Document Type: Article

References (15)

1. Bolli GB, Owens DR: Insulin glargine. Lancet 2000; 356: 443-445
2. Bray GA: Risks of obesity. Endocrinol Metab Clin North Am 2003; 32: 787-804
3. Burge MR, Schade DS: Insulins. Endocrinol Metab Clin North Am 1997; 26: 575-598
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
5. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. Jama 2003; 289: 2254-2264
6. Goodpaster BH, Krishnaswami S, Resnick H, Kelley DE, Haggerty C, Harris TB, Schwartz AV, Kritchevsky S, Newman AB: Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 2003; 26: 372-379
7. Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C: The KID Study V: the natural history of type 2 diabetes in younger patients still practising a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. Exp Clin Endocrinol Diabetes 1999; 107: 236-243
8. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620
9. Kahn SE: Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-4058
10. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19
11. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148
12. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29
13. Mudaliar S, Edelman SV: Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001; 30: 935-982
14. Waldhausl WK: The physiological basis of insulin treatment-clinical aspects. Diabetologia 1986; 29: 837-849
15. Wiesli P, Schaffler E, Seifert B, Schmid C, Donath MY: Islets secretory capacity determines glucose homoeostasis in the face of insulin resistance. Swiss Med Wkly 2004; 134: 559-564